Abtmed 250mg Tablet

Like other anticancer medicines, Abtmed 250mg Tablet also has some common to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Common side effects:

Vomiting
Diarrhea
Swelling
Joint pain
Fatigue
Cough
High BP
Constipation
Chest pain
Irregular & fast heart rate
Rashes

Severe side effects:

Urinary Tract Infection
Decreased potassium level in blood
Low blood count
Blood in urine

Abtmed 250mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Abtmed 250mg Tablet is an anticancer medicine used in hormonal therapy of prostate cancer. This medicine inhibits the action of the enzyme CYP17 which is responsible for the production of androgen and testosterone in males. It slows down the growth and multiplication of the cancer cells. Eventually, it restricts the cancer from spreading to other parts of the body and leads to death.

It is advised not to miss any scheduled dosage of Abtmed 250mg Tablet. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Abtmed 250mg Tablet is usually taken with another medicine, prednisolone to reduce unwanted side effects.

Your healthcare expert must monitor your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Abtmed 250mg Tablet can cause fluctuations in their levels.

Inform your doctor if you have diabetes, or any heart, liver, and kidney problems before taking Abtmed 250mg Tablet.

Use reliable methods of birth control and contraceptive pills to avoid pregnancy while under treatment with Abtmed 250mg Tablet.

Abtmed 250mg Tablet contains lactose and sodium, share with your physician if you have lactose intolerance.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. (2023). EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 65:467-79.

 Hellerstedt BA, Pienta KJ. (2024). The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 52:154-79.

Lu, X., Dai, T., Chen, X. et al. (2025). A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer. BMC Med 23, 271 (2025).

Mandal S, Tarigopula V, Kumaraswamy S, Das MK, Tripathy S, Barik K, Nayak P. (2024). Do Indian men have similar oncological outcomes with abiraterone plus androgen deprivation therapy in the setting of metastatic hormone-sensitive prostate cancer? A prospective observational study. Indian J Urol. 40(3):174-178.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. (2024). Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res. 68:4447-54.

Shameem R, Hamid MS, Xu KY, Wu S. (2024). Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol. 6(4):64-72.

Ye D, Huang Y, Zhou F, Xie K, Matveev V, Li C, Alexeev B, Tian Y, Qiu M, Li H, Zhou T, De Porre P, Yu M, Naini V, Liang H, Wu Z, Sun Y. (2024). A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand, and Russia. Asian J Urol. 4(2):75-85.​